Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans W Nijman

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Clinical & Developmental Immunology|December 23, 2011
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsOana Draghiciu, Hans W Nijman, Toos Daemen
Vaccines|September 8, 2015
Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte EpitopesPeng Peng Ip, Hans W Nijman, Toos Daemen
Oncoimmunology|May 8, 2015
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacyOana Draghiciu, Joyce Lubbers, Hans W Nijman, et al.
Anti-Cancer Agents in Medicinal Chemistry|November 19, 2013
HPV-specific immunotherapy: key role for immunomodulatorsStephanie Van de Wall, Hans W Nijman, Toos Daemen
Current Opinion in Oncology|June 15, 2017
Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?Florine A Eggink, Corine M Koopmans, Hans W Nijman
Antiviral Research|July 31, 2012
Therapeutic vaccination against chronic hepatitis C virus infectionPeng Peng Ip, Hans W Nijman, Jan Wilschut, et al.
Frontiers in Immunology|November 15, 2024
Genomic instability as a driver and suppressor of anti-tumor immunityMarta Requesens, Floris Foijer, Hans W Nijman, et al.
Cellular & Molecular Immunology|November 3, 2020
Tumor-infiltrating lymphocytes in the immunotherapy eraSterre T Paijens, Annegé Vledder, Marco de Bruyn, et al.
EJNMMI Research|January 5, 2024
ImmunoPET provides a novel way to visualize the CD103<sup>+</sup> tissue-resident memory T cell to predict the response of immune checkpoint inhibitorsXiaoyu Fan, Hans W Nijman, Marco de Bruyn, et al.
British Journal of Cancer|July 13, 2023
Prognostic benefit of TILs independent of clinicopathological and molecular factorsKoen Brummel, Anneke L Eerkens, Marco de Bruyn, et al.
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Clinical & Developmental Immunology|December 23, 2011
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsOana Draghiciu, Hans W Nijman, Toos Daemen
Vaccines|September 8, 2015
Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte EpitopesPeng Peng Ip, Hans W Nijman, Toos Daemen
Oncoimmunology|May 8, 2015
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacyOana Draghiciu, Joyce Lubbers, Hans W Nijman, et al.
Anti-Cancer Agents in Medicinal Chemistry|November 19, 2013
HPV-specific immunotherapy: key role for immunomodulatorsStephanie Van de Wall, Hans W Nijman, Toos Daemen
Current Opinion in Oncology|June 15, 2017
Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?Florine A Eggink, Corine M Koopmans, Hans W Nijman
Antiviral Research|July 31, 2012
Therapeutic vaccination against chronic hepatitis C virus infectionPeng Peng Ip, Hans W Nijman, Jan Wilschut, et al.
Frontiers in Immunology|November 15, 2024
Genomic instability as a driver and suppressor of anti-tumor immunityMarta Requesens, Floris Foijer, Hans W Nijman, et al.
Cellular & Molecular Immunology|November 3, 2020
Tumor-infiltrating lymphocytes in the immunotherapy eraSterre T Paijens, Annegé Vledder, Marco de Bruyn, et al.
EJNMMI Research|January 5, 2024
ImmunoPET provides a novel way to visualize the CD103<sup>+</sup> tissue-resident memory T cell to predict the response of immune checkpoint inhibitorsXiaoyu Fan, Hans W Nijman, Marco de Bruyn, et al.
British Journal of Cancer|July 13, 2023
Prognostic benefit of TILs independent of clinicopathological and molecular factorsKoen Brummel, Anneke L Eerkens, Marco de Bruyn, et al.
Pageof 17